Listed

ICU Medical Inc: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 9, 2018 and accepted by EDGAR at Nov 8, 2018, 19:29 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-07-01 to 2018-09-30$327.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2018-01-01 to 2018-09-30$1.06bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2018-07-01 to 2018-09-30$192.6mus-gaap:CostOfRevenue
Cost of revenue9 months2018-01-01 to 2018-09-30$624.3mus-gaap:CostOfRevenue
Gross profit3 months2018-07-01 to 2018-09-30$134.6mus-gaap:GrossProfit
Gross profit9 months2018-01-01 to 2018-09-30$435.4mus-gaap:GrossProfit
Research and development3 months2018-07-01 to 2018-09-30$13.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$39.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-07-01 to 2018-09-30$78.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2018-01-01 to 2018-09-30$248.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-07-01 to 2018-09-30$826.0kus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30$33.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2018-07-01 to 2018-09-30$283.0kus-gaap:InterestExpense
Interest expense9 months2018-01-01 to 2018-09-30$548.0kus-gaap:InterestExpense
Income tax3 months2018-07-01 to 2018-09-30$1.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2018-01-01 to 2018-09-30−$1.3mus-gaap:IncomeTaxExpenseBenefit
Net income9 months2018-01-01 to 2018-09-30$36.1mus-gaap:ProfitLoss
Diluted EPS3 months2018-07-01 to 2018-09-30$0.01us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30$1.67us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-07-01 to 2018-09-30$0.01us-gaap:EarningsPerShareBasic
Basic EPS9 months2018-01-01 to 2018-09-30$1.78us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-07-01 to 2018-09-3021,633,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2018-01-01 to 2018-09-3021,588,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2018-01-01 to 2018-09-30$110.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$75.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-09-30$318.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$913.3mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$1.55bnus-gaap:Assets
Current liabilitiesAt period end2018-09-30$202.5mus-gaap:LiabilitiesCurrent

Source: SEC EDGAR, the filing index for accession 0000883984-18-000029. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.